Important Note to Reader: The information in these Web pages is for your general knowledge and background only. Note that these Web pages contain information from various sources considered to be dependable. However, we make no representations, warranties or other expressed or implied warranties or guarantees regarding the accuracy, reliability or completeness of the information. Under no circumstance shall Gyrus ACMI, Inc., Olympus America Inc. and/or its or their respective affiliates, employees, consultants, agents or representatives (collectively "Gyrus") be liable for any costs, expenses, losses, claims, liabilities or other damages (whether direct, indirect, special, incidental, consequential or otherwise) that may arise from or be in incurred in connection with the information provided or any use thereof.
© 2010 Gyrus ACMI, Inc. All rights reserved. | Privacy Policy | Legal Notice
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More